Millipore Sigma Vibrant Logo

476275 Myricetin - CAS 529-44-2 - Calbiochem

A cell-permeable flavanoid that displays anti-inflammatory, anti-diabetic and anti-cancer properties.

Myricetin - CAS 529-44-2 - Calbiochem MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.

Synonyms: 3,3ʹ,4ʹ,5,5ʹ,7-Hexahydroxyflavone, Hsp70 Inhibitor II

View Products on Sigmaaldrich.com
476275
가격 및 재고 조회

개요

Replacement Information

주요 사양표

CAS #Empirical Formula
529-44-2C₁₅H₁₀O₈

가격 및 재고여부

카탈로그 번호 재고 정보패킹 포장 단위 가격(VAT 별도) 수량
476275-25MGCN
재고 정보 검색...
—
현재 재고 없음 현재 재고 없음
예상 출고 가능일 
단종품
제한된 수량 가능
재고여부 확인
    Remaining: will advise
      Remaining: will advise
      추천사항
      고객 서비스로 문의
      Contact Customer Service

      		 Plastic ampoule 25 mg
      가격 검색...
      가격을 검색할 수 없습니다
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      가격 문의 추가 정보
      ()이 할인됨
       
      —
      가격 문의
      		 —
      Description
      OverviewA cell-permeable flavanoid that displays anti-inflammatory, anti-diabetic and anti-cancer properties. Acts as a non-ATP competitive MEK1 inhibitor (IC50 < 3 µM), and ATP-competitive inhibitors of CKI, CKII, IR, MLCK, PKA and PKC (Ki = 9.0 µM, 0.6 µM, 2.6 µM, 1.7 µM, 27.5 µM and 12.1 µM, respectively) and PI 3-Kα and PIM-1 (IC50 = 1.8 µM and 0.78 µM). Reported to inhibit the activities of phosphodiesterase 1-4 (IC50 < 40 µM) and MMP-2 (IC50 < 24 µM in several colorectal carcinoma cells), and block TNFα-mediated NF-κB signaling (at 50 µM in ECV304 cells) and insulin-stimulated glucose transport (Ki = ~ 33.5 µM in rat adipocytes). Further, induce apoptosis in HL-60 leukemia cells with an IC50 of 43 µM.
      Catalogue Number476275
      Brand Family Calbiochem®
      Synonyms3,3ʹ,4ʹ,5,5ʹ,7-Hexahydroxyflavone, Hsp70 Inhibitor II
      References
      ReferencesLee, K.W., et al. 2007. Carcinogenesis 28, 1918.
      Holder, S., et al. 2007. Mol. Cancer Ther. 6, 163.
      Strobel, P., et al. 2005. Biochem. J. 386, 471.
      Ko, C.H., et al. 2005. Mol. Cancer Ther. 4, 281.
      Ko, C.H., et al. 2005. Biochem. Pharmacol. 69, 913.
      Ko, W.C., et al. 2004. Biochem. Pharmacol. 68, 2087.
      Walker, E.H., et al. 2000. Mol. Cell 6, 909.
      Agullo, G., et al. 1997. Biochem. Pharmacol. 53, 1649.
      Hagiwara, M., et al. 1988. Biochem. Pharmacol. 37, 2987.
      Product Information
      CAS number529-44-2
      FormYellowish brown solid
      Hill FormulaC₁₅H₁₀O₈
      Chemical formulaC₁₅H₁₀O₈
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥98% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      카탈로그 번호 GTIN
      476275-25MGCN 04055977184471

      Documentation

      Myricetin - CAS 529-44-2 - Calbiochem MSDS

      타이틀

      물질안전보건자료(MSDS) 

      Myricetin - CAS 529-44-2 - Calbiochem Certificates of Analysis

      TitleLot Number
      476275

      References

      참고문헌 보기
      Lee, K.W., et al. 2007. Carcinogenesis 28, 1918.
      Holder, S., et al. 2007. Mol. Cancer Ther. 6, 163.
      Strobel, P., et al. 2005. Biochem. J. 386, 471.
      Ko, C.H., et al. 2005. Mol. Cancer Ther. 4, 281.
      Ko, C.H., et al. 2005. Biochem. Pharmacol. 69, 913.
      Ko, W.C., et al. 2004. Biochem. Pharmacol. 68, 2087.
      Walker, E.H., et al. 2000. Mol. Cell 6, 909.
      Agullo, G., et al. 1997. Biochem. Pharmacol. 53, 1649.
      Hagiwara, M., et al. 1988. Biochem. Pharmacol. 37, 2987.
      Data Sheet

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision21-November-2008 JSW
      Synonyms3,3ʹ,4ʹ,5,5ʹ,7-Hexahydroxyflavone, Hsp70 Inhibitor II
      DescriptionA cell-permeable flavanoid that displays anti-inflammatory, anti-diabetic and anti-cancer properties. Acts as a non-ATP competitive MEK1 inhibitor (IC50 < 3 µM), and ATP-competitive inhibitors of CKI, CKII, IR, MLCK, PKA and PKC (Ki = 9.0 µM, 0.6 µM, 2.6 µM, 1.7 µM, 27.5 µM and 12.1 µM, respectively) and PI 3-Kα and PIM-1 (IC50 = 1.8 µM and 0.78 µM). Reported to inhibit the activities of phosphodiesterase 1-4 (IC50 < 40 µM) and MMP-2 (IC50 < 24 µM in several colorectal carcinoma cells), and block TNFα-mediated NF-κB signaling (at 50 µM in ECV304 cells) and insulin-stimulated glucose transport (Ki ~ 33.5 µM in rat adipocytes). Further, induce apoptosis in HL-60 leukemia cells with an IC50 of 43 µM.
      FormYellowish brown solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number529-44-2
      Chemical formulaC₁₅H₁₀O₈
      Structure formulaStructure formula
      Purity≥98% by HPLC
      SolubilityDMSO (5 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesLee, K.W., et al. 2007. Carcinogenesis 28, 1918.
      Holder, S., et al. 2007. Mol. Cancer Ther. 6, 163.
      Strobel, P., et al. 2005. Biochem. J. 386, 471.
      Ko, C.H., et al. 2005. Mol. Cancer Ther. 4, 281.
      Ko, C.H., et al. 2005. Biochem. Pharmacol. 69, 913.
      Ko, W.C., et al. 2004. Biochem. Pharmacol. 68, 2087.
      Walker, E.H., et al. 2000. Mol. Cell 6, 909.
      Agullo, G., et al. 1997. Biochem. Pharmacol. 53, 1649.
      Hagiwara, M., et al. 1988. Biochem. Pharmacol. 37, 2987.